Research
Small molecule

Metal protein attenuating compounds for treating neurological diseases associated with beta amyloid protein aggregation

Description and applications

Metal protein attenuating compounds (MPACs) for treating neurological diseases associated with beta amyloid protein aggregation. We have the first proof that a novel small molecule has cognition- modifying properties in a transgenic animal model of Alzheimer's disease at 20 mg/kg oral dosing over a three month period. The compound also decreased early amyloid beta cellular load by 18% in the cortex and increased by 42% the synaptophysin (synaptic marker) content in a second transgenic animal model of Alzheimer’s disease, thus indicating that the compound interferes with early amyloid aggregation and has clear neuroprotective and neurotrophic effects.

Publications

Keywords

Alzheimer, Therapy, small molecules, amyloid aggregation

Dr Adina Michael Titus

Blizard Institute

Want access?

Get in touch with the Business Development Office smd-qmbusiness@qmul.ac.uk